Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of BBV87 Chikungunya Vaccine
NCT04603131Phase 1Completed
- Sponsor
- Bharat Biotech
- Start
- Apr 2017
- Primary completion
- Jan 2018
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BBV87 in Chikungunya (CHIKV) (4 arms), sponsored by Bharat Biotech. Primary endpoint: Occurrence of adverse events and Serious Adverse events at 9 months. Started Apr 2017; status: completed.
02
Drugs
BBV87
03
Conditions
Chikungunya (CHIKV)
Beyond the preview
Go deeper on NCT04603131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04603131.